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Abstract
Background: Piperacillin levels after standard dosing have been shown frequently to be subtherapeutic, especially
when renal clearance was augmented. Here, we aimed to determine if piperacillin was in its therapeutic range in a
typically heterogeneous intensive care unit patient group, and also to describe target attainment dependent on
daily dosage, creatinine clearance, and renal replacement therapy (RRT).
Methods: Sixty patients with severe infections were included in this monocentric prospective observational study.
Patients received 4.5 g of piperacillin-tazobactam two to three times daily by intermittent infusion depending on
renal function according to clinical guidelines. Over 4 days, multiple serum samples (median per patient, 29; in total,
1627) were obtained to determine total piperacillin concentrations using ultra-high-performance liquid
chromatography/tandem mass spectrometry.
Results: A high heterogeneity of patient characteristics was observed (e.g., on day 1: creatinine clearance 2–
233 mL/min and ten patients on RRT). Piperacillin trough levels showed inter-individual variation from 123 to
>1785-fold on different study days. Each day, approximately 50 % and 60 % of the patients had piperacillin levels
below the target ranges 1 and 2, respectively [defined for the calculated unbound piperacillin fraction according to
the literature as 100 % time above MIC (100 %fT > MIC) (target range 1) and ≥ 50 %fT > 4 × MIC (target range 2);
MIC = 16 mg/L]. Whereas only the minority of patients who received piperacillin-tazobactam three times daily (TID)
reached target 1 (38 % on day 1), most patients who received piperacillin-tazobactam only twice daily (BID)
because of severely impaired renal function reached this target (100 % on day 1). Patients with RRT had significant
higher percentages of fT > MIC. Zero percent, 55 % and 100 % of patients without RRT who received antibiotics TID
reached target 1 when creatinine clearance was > 65 mL/min, 30–65 mL/min and < 30 mL/min, respectively. In
patients with causative strains only sensitive to piperacillin-tazobactam of all antibiotics given to the patient,
piperacillin levels negatively correlated with CRP concentrations of day 4 (p < 0.05).
Conclusions: A dosage of 4.5 g piperacillin-tazobactam TID seems to be frequently insufficient in critically ill
patients, and also in patients where renal function is mildly to moderately impaired. For these patients, prescription
of 4.5 g piperacillin-tazobactam four times daily could be considered.
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Background
Severe infections are a leading cause of the observed
high morbidity and mortality in intensive care unit
(ICU) patients. A key element for optimal patient out-
comes includes sufficiently high antimicrobial concen-
tration levels [1]. Such concentrations are also important
for preventing the development of antimicrobial resist-
ance [2, 3].
Piperacillin (PIP) is one of the most commonly used
antibiotics in ICUs [4, 5]. This hydrophilic drug, which
is predominantly excreted renally, is often prescribed to-
gether with the beta-lactamase inhibitor tazobactam
(TAZ) as a fixed combination. After intermittent admin-
istration, PIP concentrations varied substantially among
critically ill patients [6–10]. However, most studies have
evaluated only limited numbers of patients or defined
patient subgroups, resulting in inconclusive information
regarding just how substantial the inter-individual vari-
ation of PIP concentrations is in a typical heterogeneous
ICU patient group. Recent studies have been performed
with high patient numbers [11–13], but limited numbers
of PIP concentrations were determined per patient. In-
deed, there is only one report concerning PIP concentra-
tions over an entire 7-day antibiotic course in critically
ill patients [6]; the 11 patients included in that study ex-
hibited coefficient of variations (CV) of 20–60 % for
within-patient variability (for trough levels). Because this
variability was evaluated only in patients with normal
renal function, it remains unclear if this result reflects
the typical intra-individual variability within ICU
patients.
It has been shown that the high variability of piperacil-
lin levels observed in ICU patients often leads to poten-
tially subtherapeutic levels. This is mostly dependent on
renal function; therefore – according to expert informa-
tion and guidelines – different dosage schemes are rec-
ommended depending on creatinine clearance. Udy et
al. recently evaluated PIP levels in dependence of cre-
atinine clearance in critically ill patients with septic
shock/severe sepsis receiving 4.5 g PIP-TAZ four times
daily by intermittent short-term infusions. In patients
grouped by creatinine clearance quartiles, most patients
showed potentially insufficient PIP trough levels when
creatinine clearance was 115–170 mL/min or > 170 mL/
min [14]. Administration of 4.5 g PIP-TAZ three times
daily (TID) was also shown frequently to result in insuf-
ficient levels in critically ill patients with moderately im-
paired renal function [15]; however, this was evaluated
in the early phase of treatment, and it is not clear if this
result is transferable to later therapy time points. Indeed,
many physicians still usually prescribe only 4.5 g PIP-
TAZ TID for critically ill patients, especially for patients
with mildly or moderately impaired renal function, and
4.5 g PIP-TAZ twice daily (BID) in cases of severely
impaired renal function. Some authors assumed that the
usual reduction of the piperacillin dosage especially for
patients with severely impaired renal function might be
critical in case of serious illness. Indeed, according to
the German guideline “Epidemiology, diagnosis and
treatment of adult patients with nosocomial pneumo-
nia,” critically ill patients, in particular with a reduced
dose because of impaired renal function, might be
underdosed [16]. Therefore, it is recommended here that
the first dose should not be adapted in patients with sep-
tic shock/severe sepsis with severely impaired renal
function. However, studies describing PIP levels with
such a dosage regimen (4.5 g PIP-TAZ BID) in critically
ill patients are still lacking.
Therefore, we designed a prospective observational
study to analyze the variability of PIP in a patient group
of critically ill patients. The aim was to determine if PIP
was in its therapeutic range in a typically heterogeneous
ICU patient group and also to describe target attainment




Sixty consecutive patients who met the inclusion criteria
and who were hospitalized from September 2013 to Sep-
tember 2014 in one of three ICUs within the Depart-
ment of Anaesthesiology, University Hospital of Munich,
were included. The inclusion criteria consisted of the
presentation of severe infection (confirmed or clinically
assumed) and the therapeutic intravenous administration
of PIP-TAZ via short-duration infusions. The exclusion
criteria were age < 18 years, a planned hospitalization
time of < 4 days and the administration of PIP-TAZ
more than 48 hours before the study began. Written in-
formed consent for study inclusion was obtained from
all patients or their legal representatives.
Study design
The study protocol (NCT01793012) for this prospective
observational study was approved by the ethics commit-
tee of the Ludwig Maximilians University and was per-
formed in accordance with the ethical standards set
forth by the 1964 Declaration of Helsinki and its later
amendments. Patients received 4.5 g of PIP-TAZ BID or
TID depending on renal function according to clinical
guidelines. The beginning of the study (day 1) was de-
fined as the time point at which the first blood sample
was taken from each patient to determine PIP concen-
trations. Serum samples for antibiotic determination
were collected at multiple time points immediately be-
fore (trough level), during, and after all PIP-TAZ admin-
istrations on day 1 (sampling after the start of PIP-TAZ
administrations at 0.25, 0.5, 1.5, 4, 7.25 or 8, and
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12 hours, if appropriate). On days 2, 3, and 4, samples
were collected during only one of the PIP-TAZ intervals
(sampling at the same time points). The exact time of
blood sampling was recorded by the medical staff.
Serum samples for determination of PIP levels were im-
mediately (<15 minutes) sent by pneumatic delivery sys-
tem to the Institute of Laboratory Medicine. There,
samples were immediately centrifuged, aliquoted, stored
within 1 hour after sampling at -20 °C, and finally,
within 24 hours after sampling, at -80 °C.
Laboratory and clinical parameters
Total PIP concentrations were determined using a two-
dimensional ultra-high-performance liquid chromatog-
raphy/tandem mass spectrometry (UHPLC-MS/MS)
method as previously described [17]. Five-fold deuter-
ated piperacillin was used as the internal standard. Val-
idation revealed good analytical performance with an
inaccuracy ≤ 5 % and imprecision ≤ 5 % (CV) for all qual-
ity control samples. For renal function evaluation, 24-
hour urine was collected and creatinine clearance
(CLcrea) was calculated using the formula:
CLcrea ¼ Curine  Vurineð Þ : Cserum  timeð Þ;
where Curine is the creatinine concentration in urine,
Vurine is the urine volume, and Cserum is the serum cre-
atinine concentration. Diagnosis, laboratory and clinical
parameters/scores were recorded daily in the ICUs.
Strains
Pathogens isolated from the patients between 6 days be-
fore and 6 days after the study began were recorded.
Susceptibility to PIP-TAZ for bacteria was determined in
accordance with the breakpoints as described by the
European Committee on Antimicrobial Susceptibility
Testing [18].
Correlation of outcome parameters with PIP
concentrations
Outcome parameters (mortality within 28 days and
ICU-free days on day 28) and C-reactive protein (CRP)
levels were evaluated in all patients and in a subgroup of
patients defined as outcome group. In this group, only
patients with bacterial isolates that met all the following
criteria were included: (1) the isolates were clinically as-
sumed to be causative strains for the patients’ infection,
(2) all assumed causative strains were bacteria and were
sensitive to PIP-TAZ, (3) but not to other antibiotic sub-
stances given to the patient. PIP trough levels of day 1
were correlated with alive ICU-free days on day 28 and
with 28-day mortality. For CRP, we correlated PIP
trough levels with CRP concentrations and with changes
of CRP (CRP quotients). Finally, we correlated PIP
trough levels of day 1 with possible neurotoxic effects
within the study period (patients with delirium, somno-
lence, or seizures within the study period) in all patients.
Assessment of target concentration ranges
The thresholds for the potential therapeutic efficacy of
total PIP were defined as > 22.5 mg/L for trough levels
(target range 1) and/or a percentage of time > 90 mg/L
(%T > 90 mg/L) of ≥ 50 % (target range 2). The 22.5 mg/
L trough level corresponds to a percentage of time above
the minimal inhibitory concentration (%T >MIC) of
100 % [13, 14] using a MIC value of 16 mg/L [6, 14, 18]
and taking into account an average protein-binding frac-
tion of 30 % [12, 19–22]. Analogously, %T > 90 mg/L of
≥50 % corresponds to a %T > 4 × MIC of ≥50 % in ac-
cordance with the literature [19, 23].
Pharmacokinetic analysis
PIP trough levels, as measured using UHPLC-MS/MS,
were evaluated. For the determination of the percentage
of time the PIP concentrations remained above 90 mg/L
or 22.5 mg/L, we connected the different determined
PIP concentration points between two consecutive PIP-
TAZ administrations and determined the time point at
which the PIP concentration fell below 90 mg/L or
22.5 mg/L, respectively. The time between the beginning
of the previous PIP-TAZ administration and this time
point was set in relation to the entire time between the
two respective PIP-TAZ administrations.
Statistics
The boxplots represent the medians and interquartile
ranges, and the ends of the whiskers represent the 5th
and 95th percentiles. The intra-patient variability CV
was calculated by dividing the individual standard devi-
ation by the mean of a given patient’s trough levels. The
Spearman correlation coefficient was used to describe
the correlations between continuous parameters. The
Wilcoxon-Mann-Whitney test was used to test signifi-
cance between different groups.
Results
The beginning of the sampling was 6.9–45.6 hours (me-
dian, 18.7 hours) after the first PIP-TAZ administration.
Over the 4-day study, multiple blood samples (median,
29; interquartile range (IQR) 20–33) were taken from
each patient. The 60 patients exhibited a high hetero-
geneity in clinical and laboratory characteristics (Table 1).
The most frequent causes of infection were pneumonia
(n = 36) and peritonitis (n = 7). Twelve patients suffered
from acute respiratory distress syndrome. Seven patients
were post-lung, and eight patients were post-liver trans-
plant patients. Three patients were treated with extra-
corporeal lung assist, and ten patients were treated with
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renal replacement therapy (RRT) (day 1). In total, 33
gram-positive bacterial strains, 19 gram-negative bacter-
ial strains, 23 fungal and six viral strains were detected
in the patients.
A total of 1627 PIP concentrations were included
for evaluation. Additional file 1 shows the concentra-
tion time curves of serum PIP concentrations in all
patients. A high inter-individual variability for PIP
was observed. This result was not restricted to the
beginning of the study period (range of trough levels
on day 1: 928-fold, 0.18–167 mg/L) but was observed
over 4 days (range of trough levels 123-fold to > 1785-
fold at each day 2, 3, and 4) (Fig. 1a). The PIP con-
centration variability was similarly substantial in pa-
tients who received PIP-TAZ TID (range of trough
levels 99-fold to > 1549-fold on the different study
days) (Fig. 1b), a patient group characterized by
higher creatinine clearance (Table 1). In contrast, less
variability was observed in the PIP concentrations of
patients who received PIP-TAZ only BID (range of
trough levels 6.2-fold to 13.8-fold on the different
study days) (Fig. 1c), a patient group characterized by
the presence of strongly impaired renal function.
Intra-patient variability was much lower than inter-
patient variability. Over 4 days, only four patients exhib-
ited maximum trough levels greater than 10-fold higher
than the minimum trough levels. Most of the 60 patients
exhibited values either always (n = 22) or partly below
(n = 14) the target threshold. CVs for within-patient PIP
variability ranged from 6.4 to 129 % (median, 30 %; IQR,
23–44 %). The PIP trough level of most patients did not
change in a consistent pattern over the 4 days of the
study; only in patients 15, 17, 25, 45, and 51 we did
observe a continuous decrease, and in patient 59 a con-
tinuous increase of PIP trough levels over time
(Additional file 1).
Approximately 50 % of all study patients exhibited PIP
levels below target range 1 (trough levels < 22.5 mg/L)
(Table 2). Over 4 days, adequate trough levels of PIP
were observed in almost all patients from the patient
group with the lowest quartile of creatinine clearance
(100 % on day 1). In contrast, adequate PIP trough levels
were not observed in the patient group with the highest
quartile of creatinine clearance over the course of 4 days.
Similarly, adequate PIP trough levels were reached by al-
most all patients who received PIP-TAZ BID because of
Table 1 Clinical and demographic characteristics of included patients
Characteristica All patients Patients with 4.5 g PIP/TAZ three times daily Patients with 4.5 g PIP/TAZ two times daily
(n = 60) (n = 45) (n = 15)
Female/male (n/n) 17/43 13/32 4/11
Age (years) 63 (54–75) 63 (55–74) 64 (54–78)
BMI (kg/m2) 27 (24–29) 26 (23–29) 29 (26–31)
Severity scores
APACHE II score 24 (18–31) 24 (17–32) 24 (18–29)
SOFA score 11 (9–14) 11 (9–13) 12 (11–17)
Laboratory values
CrCl (mL/min) 60 (24–119) 70 (40–130) 11 (6–19)
Organ transplantation (n)
Lung 7 6 1
Liver 8 4 4
Special treatments (n)
RRT patients 10 7 3
ECLA 3 3 0
Site of infection (n)
Pneumonia 36 27 9
Peritonitis 7 4 3
Catheter associated 5 4 1
Others 12 10 2
Presence of ARDS (n) 12 11 1
PIP/TAZ piperacillin-tazobactam, BMI body mass index, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment,
CrCl creatinine clearance of patients without renal replacement therapy, RRT renal replacement therapy, ECLA extracorporeal lung assist, ARDS acute respiratory
distress syndrome
aData from day 1 are presented as median (interquartile range) unless otherwise specified
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impaired renal function (100 % on day 1; IQR of creatin-
ine clearance: 6–19 mL/min), whereas this target was
only reached by the minority of patients receiving PIP-
TAZ TID (38 % for PIP on day 1; IQR of creatinine
clearance: 40–130 mL/min). Indeed, in patients who re-
ceived PIP-TAZ TID (patients on RRT excluded), no pa-
tient with a creatinine clearance > 65 mL/min, and only
55 % of the patients with a creatinine clearance ranging
from 30 to 65 mL/min, reached this target (Additional
file 2). In contrast, patients with equal antibiotic dosages
and a creatinine clearance < 30 mL/min always had
piperacillin levels within the therapeutic range. The de-
pendency of trough levels on creatinine clearance was
proven (r = -0.837) (p < 0.001).
Similar observations with respect to target attainment
were made for the specific patient subgroups when using
target range 2 (≥50 %T > 90 mg/L); however, fewer pa-
tients of the patient subgroups were in the therapeutic
range (e.g., approximately 40 % of total patients over
4 days) (Table 2, Additional file 3). Whereas the differ-
ence between target attainment of target range 1 and 2
was low for patients who received PIP-TAZ TID (38 %
versus 33 % on day 1, respectively), a high difference was
observed for patients who received PIP-TAZ BID (100 %
versus 64 %) (Table 2).
Over 4 days, adequate trough levels of PIP were ob-
served in most patients with RRT (80 % on day 1)
(Table 2). Indeed, presence of RRT [different daily dos-
ages (BID or TID) and different RRT methods used, see
Additional file 4] was associated with significant higher
percentages of T > 22.5 mg/L (Fig. 2) (p < 0.001). Target
attainment of the different subgroups in dependence of
dosing, creatinine clearance, and use of RRT are shown
in Additional file 5.
PIP trough levels had no significant effects on both
mortality and ICU-free days on day 28 in all patients.
Within 28 days, six patients died, 40 patients survived
and 14 patients were discharged from hospital. The me-
dian of ICU-free days at day 28 was 14 (IQR 0–23). We
further analyzed the outcome group as defined in
Methods: also here, no significant effects of PIP trough
levels on both mortality and ICU-free days on day 28
were observed. Finally, we evaluated if PIP trough levels
might have at least an effect on the course of inflamma-
tion parameters within 4 study days. In the outcome
group, we observed a significant negative correlation be-
tween CRP concentrations on day 4 versus PIP trough
levels over time (Table 3). A similar trend for day 3 and
4 was observed when quotients of CRP concentrations
were correlated with PIP trough levels over time.
Finally, there was no difference in the presence of PIP
trough concentrations on day 1 and possible neurotoxic
effects over the study period.
Discussion
In our ICU patient group, we observed a very high
variability of PIP levels leading to a high percentage of
patients with potentially subtherapeutic PIP concentra-
tions. Target attainment was tightly associated with cre-
atinine clearance. Although the strong association
between creatinine clearance and piperacillin levels has
already been described in several studies of critically ill
patients, this work is novel in contemporary literature,
given the number of blood-sampling time points, the
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Fig. 1 Distribution of piperacillin trough levels over the course of 4 days.
Trough levels a for all patients b for patients receiving piperacillin-
tazobactam (PIP-TAZ) three times daily, and c for patients receiving
PIP-TAZ two times daily because of impaired renal function are shown.
Boxplots represent medians and interquartile ranges, and the ends of the
whiskers represent the 5th and 95th percentiles
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variability of piperacillin levels observed over several
days, the difference of target attainment dependent on
both creatinine clearance and commonly used dosage
schemes, and the increasing negative association of PIP
trough levels with CRP levels during therapy. Our data
highlights the concern that patients with mild or moder-
ate renal function impairment are also likely to have
subtherapeutic levels over several days with the
conventional intermittent dosage scheme of 4.5 g PIP-
TAZ TID. This might lead to treatment failure or the se-
lection of drug-resistant strains. In contrast, there might
be less risk of subtherapeutic trough levels and treat-
ment failure in ICU patients with severely impaired
renal function and use of RRT, even when the dosage is
reduced to 4.5 g PIP-TAZ BID.
Previous studies have also described a high depend-
ency of PIP concentrations on creatinine clearance [14,
15, 24–29]. However, only Conil et al. described the ef-
fect on target attainment when using this conventional
dosing in patients with slightly to moderately impaired
renal function [15]. They observed a correlation coeffi-
cient of -0.61, whereas we observed an even higher cor-
relation (r = -0.837) for patients receiving 4.5 g PIP-TAZ
TID. Because Conil et al. determined PIP concentrations
at precisely the time point of 24 hours after starting anti-
biotic treatment, it remained unclear if the observed
high percentage of subtherapeutic levels in their study
might also have resulted from insufficient loading and
how often the target range would be attained at a later
time points. The high correlation coefficient we found
may open the possibility to develop a pharmacokinetic
model, which might help to find adequate dosing espe-
cially in dependence of creatinine clearance values. We
showed that the percentage of insufficient levels
remained high and more or less stable in patients over
the course of several days. Moreover, all patients with a
creatinine clearance > 65 mL/min and approximately half
of patients with a creatinine clearance between 30 and
65 mL/min had insufficient levels, even with the lower
therapeutic range (therapeutic range 1). This shows that
this dosage may be insufficient over several days also for
patients who have slightly or moderately impaired renal
Table 2 Distribution of patients in relation to the target ranges of piperacillin
Patient groups, number of patientsa Percentages of patients who attain the targets
trough values≥ 22.5 mg/L ≥50 % of time > 90 mg/L
Day 1 Day 4 Day 1 Day 4
Total patients, n = 60 53 % 52 % 40 % 38 %
With lowest quartileb of CrCl, n = 11 100 % 86 % 62 % 67 %
With highest quartilec of CrCl, n = 11 0 % 0 % 9 % 0 %
With RRT, n = 10 80 % 71 % 62 % 57 %
Without RRT, n = 50 48 % 49 % 36 % 33 %
Receiving 2 × 4.5 g PIP/TAZ daily, n = 15d 100 % 82 % 64 % 50 %
Receiving 3 × 4.5 g PIP/TAZ daily, n = 45e 38 % 35 % 33 % 32 %
CrCl creatinine clearance, RRT renal replacement therapy, PIP/TAZ piperacillin-tazobactam
aNumbers as determined on day 1 are presented
bCreatinine clearance 2–19 mL/min
cCreatinine clearance 108–233 mL/min
dComprising on first study day three patients with RRT and 12 patients without RRT. The latter patients presented a median creatinine clearance of 11 mL/min
(interquartile range: 6–19 mL/min)
eComprising on first study day seven patients with RRT and 38 patients without RRT. The latter patients presented a median creatinine clearance of 70 mL/min
(interquartile range: 40–130 mL/min)
% T>22.5 mg/L






























Fig. 2 Effects of renal replacement therapy on percentage of time >
22.5 mg/L of piperacillin. Percentage of time of piperacillin (PIP) >
22.5 mg/L for values of all patients, for values of patients with renal
replacement therapy (RRT), and for values of patients without RRT
are shown. From each patient, one value was evaluated per day,
and values of the 4 days of all patients were
evaluated simultaneously
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function. To reach the target range 1, it might be rea-
sonable in cases of slightly to moderately impaired renal
function to prescribe the maximum dosage of 4.5 g PIP-
TAZ four times daily, as recommended by the prescrip-
tion drug information. However, occurrence of neuro-
toxicity, although not clearly observed in our study,
should be carefully monitored. Moreover, to the best of
our knowledge, we showed for the first time that an ad-
justed PIP dosage of 4.5 g PIP-TAZ BID for patients
with strongly impaired renal function leads to thera-
peutic levels in critically ill patients much more often
(Table 2). Interestingly, for these patients, this was much
more dependent on the defined therapeutic range (1 ver-
sus 2). Whereas most patients reached therapeutic range
1 (82–100 % at different study days), only 50–64 %
reached therapeutic range 2 (Table 2). This might be due
to the longer time intervals between consecutive doses
in this case, which makes it more difficult to reach a
high concentration over a long time interval. There is
still a controversial debate about the right target range
for critically ill patients [13]. However, the high percent-
age of patients with severely impaired renal function and
reduced dosage reaching at least the target range 1
shows that the problem of underdosing in this patient
group is much lower than in patients with slightly or
moderately impaired renal function and not an adjusted
dosage. This is still important, because many ICU physi-
cians still prescribe PIP-TAZ 4.5 g TID – at least for pa-
tients with slightly to severely impaired renal function.
Indeed, these dosages are still recommended by the Food
and Drug Administration and in expert information.
We also evaluated the influence of RRT on PIP con-
centrations. This is important as the use of RRT may
further alter antibiotic pharmacokinetics [30]. We ob-
served significant higher percentages of T > 22.5 mg/L
for the patients with RRT. Because of the different RRT
methods and the different daily dosages, we only had
limited numbers of the specific subgroups. Therefore,
we could not evaluate the influence of the different RRT
modalities on PIP concentrations.
Table 3 Analysis of outcome groupa
Correlation of piperacillin trough levelsb with CRP levels Number of patients Correlation coefficient p value
Trough level day 1 versus CRP day 1 13 0.13 0.67
Trough levels day 1 + 2 versus CRP day 2 13 - 0.22 0.94
Trough levels day 1 + 2 + 3 versus CRP day 3 12 - 0.31 0.33
Trough levels day 1 + 2 + 3 + 4 versus CRP day 4 11 - 0.66 0.028*
Trough levels day 1 + 2 versus the quotient CRP day 2/1 13 - 0.12 0.71
Trough levels day 1 + 2 + 3 versus the quotient CRP day 3/1 12 - 0.50 0.095
Trough levels day 1 + 2 + 3 + 4 versus the quotient CRP day 4/1 11 - 0.55 0.083

















aIn this group, only patients with bacterial isolates that met all the following criteria were included: (1) the isolates were clinically assumed to be causative strains
for the patients’ infection, (2) all assumed causative strains were bacteria and were sensitive to PIP-TAZ, (3) but not to other antibiotic substances given to
the patient
bOnly one piperacillin trough level used per day
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Considering all patients, we observed a high variability
and a high quantity of subtherapeutic levels for PIP, as
in other studies [6, 9, 19, 21, 31, 32]. In contrast with
the literature, we observed an even higher inter-
individual variability for PIP trough levels [6, 9, 19, 21,
33] and a higher percentage of patients with PIP levels
below fT >MIC [6, 9, 14] and below the higher target
range of 50 % fT > 4 × MIC [9, 19, 23]. Sime et al., how-
ever, observed a higher percentage of patients with
trough levels below the target range [21], which might
be due to the average higher creatinine clearance (all pa-
tients > 50 mL/min) of their study patients. The high
inter-individual variability we observed in our study with
trough levels varying > 100-fold was restricted to patients
who received PIP-TAZ TID (Fig. 1), which might be at
least in part due to the higher range of creatinine clear-
ance in this group. We also found partly higher intra-
patient variability than in the literature: over 4 days, we
observed CVs for PIP ranging from 6 to 129 %, whereas
Carlier et al. reported CVs of 20–60 % over an entire
antibiotic course [6]. The reason for the higher variabil-
ity observed in our study might be the higher heterogen-
eity of patient characteristics. As this is typical for ICU
patients, our data might support the concept of thera-
peutic drug monitoring (TDM).
Thresholds of both target ranges for unbound PIP
were defined as in other studies [6, 9, 14, 19, 21, 23]. A
traditional target for this antibiotic is 40–50 %fT >MIC
[34]. However, a higher target range might be more ap-
propriate for ICU patients [31] because of the critical ill-
nesses of these patients. Therefore, we chose 100 %fT >
MIC in accordance with most other studies [6, 9, 14,
21]. Indeed, different studies demonstrated that for beta-
lactam antibiotics, maximum killing is often only
achieved when the T >MIC approaches 90–100 % of the
dosing interval [35]. The higher target range (50 %fT > 4
× MIC) was chosen in accordance with other studies
[19, 23], because antibacterial killing of beta-lactam anti-
biotics might be maximal when the antibiotic is 4–5 ×
MIC [36]. A long time-interval above such a higher
threshold might also be positive to reduce the develop-
ment of antibiotic resistance [3]. However, it should be
noted that even higher target ranges (i.e., 100 %fT > 4 ×
MIC) might be useful to maximize the antimicrobial ef-
fect and minimize the development of resistance in these
patients [3, 19]. Target attainment might also vary in de-
pendence of microorganism idiosyncrasies such as in-
oculum [37]. Future prospective interventional studies
are required to investigate which target ranges are asso-
ciated with the best outcome for patients, thereby also
minimizing the risk for the development of antibiotic re-
sistance in the intensive care unit.
Outcome parameters such as alive ICU-free days, 28-
day mortality, or occurrence of adverse reactions did
not correlate with PIP levels in all patients. However,
because of the patient number and the heterogeneous
patient group used, short-term effects of antimicrobial
therapy on alive ICU-free days and 28-day mortality
might not be visible in this group. We therefore also
correlated CRP concentrations in both all patients and
in the outcome group. In the outcome group, we found
a negative correlation of CRP concentrations at day 4
with PIP trough levels (p < 0.05). Furthermore, a trend
to a faster CRP decrease in cases of high PIP trough
levels was also observed at day 3 and 4 (both p < 0.1,
Table 3). We thought that it might be important to de-
fine an outcome group, because we wanted to evaluate
only relevant patients, where PIP-TAZ was the only
antimicrobial therapy effective against the causative
pathogens. As it has not yet been shown in the literature
for piperacillin that target attainment of our targets cor-
relates with a positive clinical or microbiological out-
come, the targets used in our study have to be regarded
only as a limited approach. However, our data indicate
that at least higher concentrations of PIP might be asso-
ciated with a faster decrease of the inflammation param-
eter CRP.
This study has some limitations. (1) The data were
drawn from a single center. Indeed, PIP pharmacokinet-
ics might be different among patients from different
ICUs. To minimize this limitation, we included a rela-
tively high number of patients and allowed a high het-
erogeneity of patient characteristics to best represent the
full spectrum of different patients in ICUs. (2) We did
not measure the unbound fraction of PIP from stored
serum samples, e.g., via centrifugal filter devices. Indeed,
it remains unclear if PIP might be bound to the filter in
a relevant percentage and if freeze-thaw cycles might
alter the protein-binding fraction. However, we consid-
ered a fixed protein-binding fraction of 30 % in the defi-
nitions of the target ranges. This may be a problem in
individual patients, because unbound PIP fractions may
differ substantially in individual critically ill patients, es-
pecially in those with altered protein levels. (3) Higher
thresholds of the target ranges were not defined, as no
robust data are existent. However, definition of such
thresholds may also be important because it has been
shown that the neurotoxicity of some beta-lactam antibi-
otics may be probably underestimated in critically ill pa-
tients [38]. (4) Only two different dosing schemes were
evaluated. Some authors have used higher doses for crit-
ically ill patients [6, 14]; however, the dosage schemes
used in our study are still recommended by the Food
and Drug Administration and in expert information.
Prolonged or continuous infusions have also been rec-
ommended [34]. Indeed, it has been shown by Abdul-
Aziz et al. that prolonged infusion of piperacillin can be
associated with a better outcome [39] but no difference
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in the clinical outcome was observed in other studies
[40, 41]. Moreover, some authors also write that a pro-
longed or continuous infusion eventually promotes that
resistant mutants are selectively amplified, and that these
mutants therefore might become the dominant bacterial
population [2] (5) Finally, we did not use pharmacoki-
netic modeling to describe %T > 90 mg/L or trough
levels. Such models are especially relevant if only few
samples per patient are available or if concentrations
around the peak value have to be described. We did not
perform pharmacokinetic modeling because we collected
multiple blood samples between consecutive antibiotic
administrations (Additional file 1), and we only de-
scribed the %T > 90 mg/L and the trough levels, which
were always on the descending concentration time
curves. Indeed, imprecise individual predictions might
occasionally occur with pharmacokinetic modeling if the
individual estimated parameter values vary substantially
from those of the typical population, which might be a
problem in a highly heterogeneous patient group as in
our study [42].
Conclusions
Our data emphasize that the conventional dosing of
4.5 g PIP-TAZ TID may often lead to insufficient
blood levels in critically ill patients, and also in pa-
tients with slightly or moderately impaired renal func-
tion. In contrast, underdosing might be less common
in patients with severely impaired renal function or in
patients with RRT, also in cases of 4.5 g PIP-TAZ
BID.
Key messages
 A high inter- and intra-individual variability of
piperacillin levels was observed leading to a continu-
ously high percentage of potentially subtherapeutic
levels over several days during the acute phase of
severe infections.
 Piperacillin trough levels were tightly associated
with creatinine clearance.
 Only the minority of patients who received PIP-TAZ
4.5 g TID had trough levels for the calculated
unbound fraction of piperacillin > 16 mg/L (target
range 1), whereas most patients who received PIP-
TAZ 4.5 g only BID because of severely impaired
renal function attained this target range.
 Use of renal replacement therapy led to significant
higher percentages of T > 16 mg/L for the calculated
unbound fraction of piperacillin.
 In patients with causative strains only sensitive to
PIP-TAZ of all antibiotics given to the patient,
piperacillin levels negatively correlated with CRP
concentrations of day 4 (p < 0.05).
Additional files
Additional file 1: Piperacillin serum concentrations of all patients. A
figure showing the piperacillin serum concentrations of all patients over
the course of 4 days. Piperacillin concentrations from two to three
administrations on day 1 and from one administration on day 2–4 are
presented. Single points always represent trough levels; 1patient number
of each subfigure. (PPTX 838 kb)
Additional file 2: Piperacillin trough levels in relation to creatinine
clearance for patients who received 4.5 g piperacillin-tazobactam three
times daily. A figure showing piperacillin levels in relation to creatinine
clearance. Only patients without use of renal replacement therapy are
shown. The second trough level, if available, is presented per day and per
patient. (PPTX 51 kb)
Additional file 3: Distribution of percentage of time with piperacillin
values > 90 mg/L. A figure showing the percentage of target attainment
of target 2 (≥50 % > 90 mg/L) in different patient subgroups. Percentage
of time of piperacillin > 90 mg/L (a) for all patients, (b) for patients
receiving piperacillin-tazobactam three times daily and (c) for patients
receiving piperacillin-tazobactam two times daily because of impaired
renal function are shown. Boxplots represent medians and interquartile
ranges, the ends of the whiskers represent the 5th and 95th percentiles.
(PPTX 1153 kb)
Additional file 4: Renal replacement therapy and dosage of piperacillin-
tazobactam A table showing the type of renal replacement therapy and
the daily dosage for each patient. CVVHD, continuous veno-venous
hemodialysis; CVVH, continuous veno-venous hemofiltration; CVVHDF,
continuous veno-venous hemodiafiltration; IHD, intermittent
hemodialysis; TID, piperacillin-tazobactam 4.5 g three times daily; BID,
piperacillin-tazobactam 4.5 g twice daily. (DOCX 15 kb)
Additional file 5: Target attainment in dependence of subgroups. A
table showing the target attainment of values in dependence of actual
piperacillin-tazobactam dosage, creatinine clearance, and use of renal
replacement therapy. From each patient, one value was evaluated per
day in the corresponding subgroup (each day grouped in dependence
of the actual creatinine clearance, dosage of piperacillin, or actual use of
renal replacement therapy). All values of all days of the different sub-
groups were evaluated simultaneously. TID, piperacillin-tazobactam 4.5 g
three times daily; BID, piperacillin-tazobactam 4.5 g twice daily; CrCl
creatinine clearance; RRT, renal replacement therapy. 1The second trough
levels, if available, was evaluated per day and per patient; 2values from
the first to the second piperacillin-tazobactam administration were used,
if available, per day and per patient; 3this subgroup included values of
the two patients with the highest body mass index, i.e., 37 and 41 kg/m2.
(DOCX 15 kb)
Abbreviations
%T> 90 mg/L: percentage of time >90 mg/L; %T >MIC: time above the minimal
inhibitory concentration; BID: twice daily; CRP: C-reactive protein; CV: coefficient of
variations; fT >MIC: time above the minimal inhibitory concentration for the
unbound antibiotic; ICU: intensive care unit; IQR: interquartile range;
PIP: piperacillin; RRT: renal replacement therapy; TAZ: tazobactam;
TDM: therapeutic drug monitoring; TID: three times daily; UHPLC-MS/MS: ultra-
high-performance liquid chromatography/tandem mass spectrometry.
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